From Research at med.fsu.edu Tue Jan 7 15:51:51 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 7 Jan 2020 20:51:51 +0000 Subject: Limited Submission first-come first-nominated: Agilent Early Career (PhD no later than January 2010) Professor Award In-Reply-To: <8ACDDC4E-D519-41C1-ACD7-EB6045BE650D@med.fsu.edu> References: <8ACDDC4E-D519-41C1-ACD7-EB6045BE650D@med.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904594F0@FSUCOM128.med.ad.fsu.edu> The internal deadline for the Agilent Early Career Professor Award has passed, and therefore the first early career (PhD no later than January 2010) professor to claim FSU?s spot will get this Limited Submission nomination. To claim the nomination and submit the application on February 28, go to https://www.research.fsu.edu/limitedsubmission/, locate the Agilent entry, and then use the ?contact OPD? email button (and please cc research at med.fsu.edu). 2020 focus of the competition: Contributions to the development of breakthrough live cell analysis technologies for measuring cellular responses to chemical/pharmaceutical treatments and genetic manipulations, including those that could advance cell-based therapies. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Jan 10 16:06:11 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 10 Jan 2020 21:06:11 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190459714@FSUCOM128.med.ad.fsu.edu> Reminder from NIH regarding ORCID iD registration NIH encourages everyone from graduate students to senior scientists to register for an ORCID account and link it to their eRA Commons personal profile (see this eRA video for a quick step-by-step). But for some grant applicants, it?s an absolute must. ORCID iDs are required for PD/PIs on individual fellowship and career development applications submitted for due dates on or after January 25, 2020. NIH eRA systems will check the PD/PI eRA Commons IDs on all submitted fellowship and career development applications. If there isn?t a linked ORCID iD, an error will be generated preventing the application from moving forward to NIH for consideration. For more details, see the full Guide Notice or the Open Mike blog on this topic. Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10. Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10. Biospecimen Science Technologies for Basic and Clinical Cancer Research Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10. Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10. Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 / U01 Clinical Trial Optional) R01 The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. U01 The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10. Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project?s originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data. Due February 26, 2020; October 28, 2020; February 26, 2021; October 28, 2021; February 26, 2022; October 28, 2022. Med-RA deadline to receive draft documents for February 26, 2020 deadline: February 13. Fine-Mapping Genome-Wide Associated Loci to Identify Proximate Causal Mechanisms of Serious Mental Illness (R01 Clinical Trial Not Allowed) Genome-wide association studies (GWAS) have identified statistical relationships between tens of thousands of common single nucleotide variants and over a thousand traits. Due to the correlated nature of nearby genetic variants, GWAS implicate regions of the genome and do not necessarily pinpoint the causal variant(s), gene(s) or mechanism(s) underlying the trait association. The purpose of this funding opportunity announcement is to support systematic fine-mapping of genome-wide significant risk loci associated with serious mental illnesses through robust statistical genetic and functional genomic approaches. Due February 28, 2020. Med-RA deadline to receive draft documents: February 17. Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called ?competing revisions?) from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as ?assays?) to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as ?markers? or ?biomarkers?) for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices. Due February 28, 2020; July 10, 2020; October 27, 2020; February 26, 2021; July 13, 2021; October 26, 2021; February 28, 2022; July 11, 2022; and October 28, 2022. Med-RA deadline to receive draft documents for February 28, 2020 deadline: February 17. Laboratories to Optimize Digital Health (R01 Clinical Trial Required) NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention?s effectiveness. Due March 2, 2020 and November 2, 2020. Med-RA deadline to receive draft documents for March 2, 2020 deadline: February 18. 4DN Organization and Function in Human Health and Disease New Investigator Projects on 4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed) To support projects from scientists who are in the early stages of establishing an independent research career that apply new or existing tools to monitor and/or manipulate the 4D nucleome (4DN) in the context of human health and disease. Any human disease or biological process relevant to NIH?s mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant time frames may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles. Due March 2, 2020. Med-RA deadline to receive draft documents: February 18. 4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed) To support projects that apply new or existing tools to monitor and/or manipulate the 4D nucleome in the context of human health and disease. Any human disease or biological process relevant to NIH?s mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant timeframes may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles. Due March 2, 2020. Med-RA deadline to receive draft documents: February 18. 4DN Centers for Data Integration, Modeling and Visualization (UM1 Clinical Trial Not Allowed) The purpose of this FOA is to solicit applications for research projects to generate reference datasets and to create navigable maps for the study of the spatial and temporal organization of the nucleus, using genomic and imaging data as well as newly developed visualization and integrative analysis tools. Due March 17, 2020. Med-RA deadline to receive draft documents: March 4. Real Time Chromatin Dynamics and Function (U01 Clinical Trial Not Allowed) To support the development and application of tools that would enable the monitoring in real-time of the dynamic three-dimensional structure of mammalian genomes and provide insight into how organizing components of 4D genome architecture affect biological processes in live cells. Due March 17, 2020. Med-RA deadline to receive draft documents: March 4. Transformative Technology Development for the Human BioMolecular Atlas Program (UG3 / UH3 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues, particularly for characterizing functional modifications, lipids and the extracellular environment. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for 3D mapping the human body with high resolution. Due March 3, 2020. Methods and Measurement in Research with Sexual and Gender Minority (SGM) Populations (R21- Clinical Trials Not Allowed) The purpose of this initiative is to support research projects to advance the measurement of constructs relevant to health research with sexual and gender minority (SGM) populations. Due March 3, 2020. Med-RA deadline to receive draft documents: February 19. Clinical Trials Planning for Symptomatic Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R34 Clinical Trial Not Allowed) The emerging science of vascular contributions to cognitive impairment and dementia (VCID) includes a spectrum of cerebrovascular and cardiovascular diagnoses that negatively impact brain health to the point of resulting in or adding to the burden of cognitive impairment, including dementia. The purpose of this initiative is to provide two years of support for planning activities necessary to initiate a Phase III, maximum five-year clinical trial to evaluate efficacy of interventions for patients with symptomatic VCID. The planning grant mechanism is designed to: 1) Permit early peer review of the rationale for the proposed clinical trial; 2) Permit assessment of the overall design of the proposed trial; 3) Provide support for the development of documents needed for the conduct of the trial, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the trial. The proposed clinical trial should address VCID treatment in a well-defined subset of VCID and utilize validated biomarkers as appropriate. Clinical trial planning activities carried out with awards funded under this RFA may include, but are not limited to, establishment of the research team and collaborations, development of tools for data management and oversight of the trial, designing trial protocols, procedure manuals, and recruitment strategies; collecting feasibility data; and addressing regulatory approvals. Due March 31, 2020. Med-RA deadline to receive draft documents: March 18. Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support the development of novel therapeutics which are directed to intracellular HIV targets. During the HIV life cycle multiple viral associated proteins are expressed in the infected cell. All are critical to support assembly, release and maturation of the virus. Considering each protein has a defined role in the life cycle, therapeutically targeting one or more may be an effective strategy to obtain potent antiviral activity. Due April 1, 2020. Med-RA deadline to receive draft documents: March 19. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue Jan 21 11:07:01 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 21 Jan 2020 16:07:01 +0000 Subject: Weekly Funding Opportunities Message-ID: Klingenstein-Simons Fellowship Awards in Neuroscience The Esther A. & Joseph Klingenstein Fund and the Simons Foundation are inviting applications for the Klingensten-Simons Fellowship Awards in Neuroscience, among the nation's oldest and most illustrious fellowships for young investigators in neuroscience research. Through the program, fellowships of $225,000 over three years will be awarded to young investigators in support of basic or clinical research that leads to a better understanding of neurological and psychiatric disorders. Areas of particular interest within the neurosciences include: * Cellular and Molecular Neuroscience ? Studies of the mechanisms of neuronal excitability and development, and of the genetic basis of behavior. * Neural Systems ? Studies of the integrative function of the nervous system. * Translational Research ? Studies designed to improve the prevention, diagnosis, treatment and our understanding of the causes of neurological and psychiatric disorders. Eligibility: The candidate must be an independent investigator at a university, medical center or research institute and be within 4 years of completing postdoctoral training and the start of his/her tenure track or equivalent appointment (between July 1, 2016 and July 1, 2020). Due February 15, 2020. Med-RA deadline to receive draft documents: February 3. New York Stem Cell Foundation: Neuroscience Investigator Awards The mission of the New York Stem Cell Foundation is to accelerate cures for major disease through stem cell research. To that end, the foundation welcomes applications for its Neuroscience Investigator Awards. Through the program, grants of $1.5 million over five years will be awarded to early-career investigators in support of bold, innovative research with the potential to transform the field of neuroscience. Applicants need not be working in areas related to stem cells or related areas, and applications are encouraged in all areas of neuroscience. Due February 19, 2020. Med-RA deadline to receive draft documents: February 6. Livestrong Solution Grants The LIVESTRONG Foundation?s LIVESTRONG Cancer Institute works to rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship, and end-of-life care ? all with a focus on the patient?s needs, values, and preferences. To advance this mission, the institute is inviting applications for its LIVESTRONG Solution Grants. Through the program, grants will be awarded in support of inventive, cutting-edge solutions to overlooked problems in cancer. Funding priorities include post-treatment care; patient and caregiver education; comprehensive quality-of-life services; and streamlining systems and care. The foundation provides two levels of funding: grants of up to $20,000 through its Acceleration Grants program, and grants of up to $100,000 through its Transformation Grants program. Letters of intent due February 21, 2020. Med-RA deadline to receive draft documents: February 10. AstraZeneca HealthCare Foundation: Connections for Cardiovascular Health (CCH) CCH provides grants to U.S.-based nonprofit organizations engaged in charitable work at the community level in the United States in support of the program?s mission. Since its inception in 2010, the Foundation?s CCH program has funded programs providing innovative, community-based approaches to improving cardiovascular health across the United States. CCH-funded programs use culturally appropriate approaches with measurable outcomes to address specific unmet needs of communities across the country, especially underserved communities. Through the program, grants in the amount of $125,000 to $150,000 over one year will be awarded to eligible organizations that have never been funded by the foundation through the CCH program. Due February 21, 2020. Med-RA deadline to receive draft documents: February 10. U.S. NAM Catalyst Award Competition: Healthy Aging As part of the Healthy Longevity Global Competition, the U.S. National Academy of Medicine (?NAM?), with support from Johnson & Johnson Innovation, will issue up to 24 Catalyst Awards per year between 2020 and 2022. Each Catalyst Award includes a $50,000 cash prize as well as travel costs to attend an annual Innovator Summit, beginning in summer 2021. The American Federation for Aging Research (AFAR) will collaborate with the NAM on the application and scientific review process. Catalyst Awards will reward bold, new, potentially transformative ideas to improve the physical, mental, or social well-being of people as they age, in a measurable and equitable way. In particular, we seek ideas that aim to extend the human healthspan through innovative approaches. Applications may originate from any field or combination of fields (e.g., biology, chemistry, medicine, engineering, infrastructure, behavioral and social sciences, technology, and policy). Ideas may focus on any stage of life, as long as they ultimately promote health as people age. Examples of topic areas include but are not limited to: * Biology of aging and molecular pathways * Physical health (e.g., mobility and functionality) * Built environment and urban planning * Disease prevention, including biomarkers and indicators of disease * Health care delivery * Housing (e.g., smart-enabled homes, intergenerational housing models) * Policy (e.g., economic, health, and science policy) * Behavioral health (e.g., social connectedness, engagement, and well-being) * Technology (e.g., artificial intelligence; robotics; medical, assistive, and information-technology) Due February 24, 2020. Med-RA deadline to receive draft documents: February 11. Robert Wood Johnson Foundation: Interdisciplinary Research Leaders Interdisciplinary Research Leaders (IRL) is a three-year national leadership development program that aims to foster and support new interdisciplinary, action-oriented research collaborations that will help build the evidence base for effective community interventions to improve health for all. The 2020 cohort will focus on either of these two themes: Community Environment and Health or Families and Child Health. We?ll support teams of mid-career individuals who come from diverse disciplinary backgrounds or scientific perspectives. The community-engaged partner on the team may work in a variety of organizational settings and have relevant expertise in the proposed research project. For the 2020 cohort, we will select up to 15 teams of three mid-career individuals each (two researchers and a community partner per team). The applicant organization will receive up to $350,000, including $25,000 per year per fellow, and a portion of the $350,000 to the team toward research activities. Those selected to participate in IRL can expect to: * Develop, execute, and disseminate a detailed proposal for the team?s specific research project; * Participate in weekly online learning activities, networking, and occasional in-person meetings (2?3 times per year); * Increase expertise in interdisciplinary research team-building and authentic community engagement; * Enhance competencies in a variety of rigorous qualitative and quantitative research methodologies, and better interpret findings and leverage them for action; * Have an understanding of the constraints to action (e.g., structural racism in historical and contemporary contexts); * Enhance skills to ensure ethical research and community standards remain a priority; * Understand the policy process and how best to communicate research evidence to inform policy. Due March 11, 2020. Med-RA deadline to receive draft documents: February 27. Robert Wood Johnson Foundation: Clinical Scholars Clinical Scholars is a three-year, team-based program for a wide variety of health professionals in community, clinical, or academic settings. By the end of the program, fellows will have gained the skills they need to appraise, synthesize, use the best evidence to guide practice and inform policy in addressing complex health problems in their teams, organizations, and communities. We are seeking up to 35 individuals (in teams of three to five) with the potential to become national change leaders in their focus areas and a demonstrated long-term commitment to fostering and achieving health equity. Those selected for this program will engage in: * Personal, in-depth leadership training in health equity and community engagement * Collaborative work across disciplines and professions to tackle problems that emerge from complex systems in communities * Robust and customizable distance-based learning (8?10 hours/month) * Required in-person team meetings/activities three times per year * Planning and implementation of your team?s ?Wicked Problem Impact Project? * Receipt of grant funds based on team size (from up to $315,000 for a three-person to $525,000 for a five-person team) * Mentoring and networking across all Clinical Scholars cohorts, other RWJF leadership programs, and with experts nationwide. Due March 11, 2020. Med-RA deadline to receive draft documents: February 27. NSF: Enabling Discovery through GEnomic Tools (EDGE) A comprehensive understanding of the functional mechanisms that connect genotype-to-phenotypes is a grand challenge in biology. Support for research on diverse organisms is critical for developing strong inferences about the rules governing the mechanisms that bidirectionally connect genomes and phenomes. The objective of the EDGE program is to provide support for genetic and/or genomic research and associated theory, approach, tool, and infrastructure development that address the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. The EDGE program will accept proposals to two submission tracks: FUNCTIONAL GENOMIC TOOLS TRACK: Proposals submitted to this track should propose to develop and provide proof-of-concept tests of functional genomic tools and infrastructure to enable direct tests of hypotheses about gene function in diverse plants, animals, microbes, viruses or fungi for which such tools and infrastructure are presently unavailable. Examples of relevant objectives for plants, animals, microbes, viruses or fungi for which such tools and infrastructure are presently unavailable include, but are not limited to: * Development of mutant libraries and/or high-quality reference genomes * Expansion of the use of gene editing, knock-out, and overexpression approaches for manipulating individual genes or interrogating multiple genes simultaneously in diverse organisms; * Development of approaches to test gene function in a variety of targeted, single cells in organisms; * Generalizable high throughput phenotyping methods; * Innovative approaches for establishing function of single or networks of genes; and * Development and testing of transformation approaches. COMPLEX MULTIGENIC TRAITS TRACK: Prior investments of the EDGE program have led to more wide-spread examination of genome(s)-to-phenome(s) relationships in many emerging model plants, animals, microbes, viruses and fungi. However, in these systems functional genomics has largely been limited to identifying candidate genes followed by single gene manipulation. Although, single gene manipulation allows interrogation of genes of large effect it does not significantly advance our understanding of complex multigenic organismal traits across a variety of contexts (i.e. environmental, developmental, social and/or genomic). The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding complex traits requires systems-level analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to this track may include but are not limited to: * Systems-level analysis of the gene regulatory networks underlying complex traits; * Elucidation of the causal connections across levels of biological organization that underlie complex multigenic traits; * New or innovative analytical approaches to linking genes and complex traits; and * Multi-genome/epigenome interactions with the environment towards the goal of predicting complex organismal phenotypes across contexts. Budget requests should be commensurate with the goals of the project. The EDGE program expects to make awards covering the full range of budget requests commensurate with the size and scope of each project. Proposals accepted anytime. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. You have received this email because you are subscribed to the College of Medicine Funding Opportunities Listserv. If you no longer wish to receive funding opportunity emails and the monthly Med-RA Newsletter from the College of Medicine Funding Opportunities Listserv, please click here to unsubscribe. If you received this as a forwarded email and would like to subscribe to the Listserv, click here. Thank you. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Jan 30 14:13:54 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 30 Jan 2020 19:13:54 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190459BA7@FSUCOM128.med.ad.fsu.edu> BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional) A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed. Due March 24, 2020; June 2, 2020; October 1, 2020; February 2, 2021; June 1, 2021; October 1, 2021; February 1, 2022; June 1, 2022; and October 3, 2022. Med-RA deadline to receive draft documents for March 2020 deadline: March 11. Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21 / R01 - Clinical Trial Not Allowed) R21 R01 The purpose of these initiatives is to support multidisciplinary research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver diseases and liver cancer in the U.S. Due April 1, 2020; April 1, 2021; and April 1, 2022. Med-RA deadline to receive draft documents for April 2020 deadline: March 19. Alzheimer's Drug Discovery Foundation: Prevention Beyond the Pipeline The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports: 1. Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. 2. Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology. 3. Studies of Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under ?Funding Priorities for Clinical Trial Proposals? and ?Evaluation of Clinical Trial Proposals?. Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk. Average duration: One year for epidemiological analyses. Varies (multi-year) for clinical trials. Average Award: $50,000-$100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research. Letter of intent due April 10, July 10, and October 9, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: March 30. Alzheimer's Drug Discovery Foundation: Drug Development Program The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years. Specifically, the Drug Development RFP supports: * Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability * In vivo efficacy or proof-of-concept studies Applications that focus on basic science, target identification, target validation, assay development, and high-throughput screening are not a priority for this RFP and will be withdrawn. The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other disease indications are appropriate for this RFP. Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors. Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered. Average Award: $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Letter of intent due April 10, 2020; July 10, 2020; and October 9, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: March 30. Mendelian Genomics Research Centers (U01 - Clinical Trial Optional) The purpose of this Funding Opportunity is to establish a consortium aimed at significantly increasing the proportion of Mendelian conditions with an identified genetic cause. A key objective of the Mendelian Genomics Research Centers is to develop and apply approaches to discover causal genes underlying Mendelian conditions for which a candidate gene was not identified using whole exome sequencing alone. Due April 15, 2020. Med-RA deadline to receive draft documents: April 2. Research Answers to National Cancer Institute?s (NCI) Provocative Questions (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI?s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these ?Provocative Questions? (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to these FOAs must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ. PQs: * What are the underlying causes of the unexplained rising incidence in early-onset cancers? * How does intermittent fasting affect cancer incidence, treatment response, or outcome? * How do selective pressures affect cell competition and cooperation during cancer initiation and development? * What mechanisms explain sex differences in cancer incidence, lesion location, or response to therapy? * What strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments? * How can cancer cachexia be reversed? * What methods can be developed to integrate patient-generated health data into electronic health records? * What strategies improve and sustain coordination of comprehensive healthcare for underserved cancer patients with comorbidities? * What methods can be developed to effectively study small or rare populations relevant to cancer research? Due April 30, 2020 and November 17, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: April 20. National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11. Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on the following: Curriculum or Methods Development: This FOA is intended to support the development of a multi-disciplinary clinical and translational geriatrics-related research curriculum that will be used in future training programs for clinician-scientists. Such resource development will fill a need not currently addressed by existing NIH- and NIA-supported programs. Proposed resources should improve geriatrics research education through innovative programs, novel instructional approaches, computer-based tools, problem-based learning, and other effective strategies. Specific research education topics may include, but are not limited to, the following: * Scientific approaches to prevention and management of multimorbidity * Clinical investigation and clinical trials of geroscience-related interventions * Development and incorporation of functional outcomes into clinical studies * Research approaches toward treatment of geriatric conditions and disease management within a geriatric framework * Recruitment of diverse populations of older adults into clinical research studies * Research approaches to geriatric health disparities Courses for Skills Development: In addition to development of a curriculum, this FOA can also support testing and refinement of the curriculum through courses. Such implementation, if proposed, is expected in the latter years of the R25 award. Research Experiences: If warranted, this FOA can also support hands-on research experiences for the purposes of testing and refining the curriculum in the latter years of the R25 award. Standard dates apply. Expires January 26, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11. Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms. Due May 27, 2020; May 26, 2021; and May 24, 2022. Med-RA deadline to receive draft documents for May 2020 deadline: May 13. NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for proposed research. Due June 11, 2020; January 11, 2021; June 11, 2021; January 11, 2022; and June 10, 2022. Med-RA deadline to receive draft documents for June 2020 deadline: May 13. Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed) Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging. Due June 17, 2020. Med-RA deadline to receive draft documents: June 4. Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed) This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors involved, the multiple cell types involved, and the mechanisms underlying rejuvenation or accelerated aging that are observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation or accelerated aging will be obtained from research supported under this FOA. Due June 17, 2020. Med-RA deadline to receive draft documents: June 4. NSF: Developmental Sciences (DS) DS supports basic research that increases our understanding of cognitive, linguistic, social, cultural, and biological processes related to human development across the lifespan. Research supported by this program will add to our knowledge of the underlying developmental processes that support social, cognitive, and behavioral functioning, thereby illuminating ways for individuals to live productive lives as members of society. DS supports research that addresses developmental processes within the domains of cognitive, social, emotional, and motor development across the lifespan by working with any appropriate populations for the topics of interest including infants, children, adolescents, adults, and non-human animals. The program also supports research investigating factors that affect developmental change including family, peers, school, community, culture, media, physical, genetic, and epigenetic influences. Additional priorities include research that: incorporates multidisciplinary, multi-method, microgenetic, and longitudinal approaches; develops new methods, models, and theories for studying development; includes participants from a range of ethnicities, socioeconomic backgrounds, and cultures; and integrates different processes (e.g., memory, emotion, perception, cognition), levels of analysis (e.g., behavioral, social, neural), and time scales. The budgets and durations of supported projects vary widely and are greatly influenced by the nature of the project. Investigators should focus on innovative, potentially transformative research plans and then develop a budget to support those activities, rather than starting with a budget number and working up to that value. While there are no specific rules about budget limitations, a typical project funded through the DS program is approximately 3 years in duration with a total cost budget, including both direct and indirect costs, between $100,000 and $200,000 per year. Due July 15, 2020. January 15 and July 15 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 1. NSF: Social Psychology The Social Psychology Program at NSF supports research and research infrastructure to advance basic knowledge in social psychology. Projects funded by the Social Psychology Program support the NSF mission to promote the progress of science; to advance the national health, prosperity, and welfare; and to secure the national defense. Proposed research should carry strong potential for creating transformative advances in the basic understanding of human social behavior. Among the many research topics supported are: social cognition, attitudes, social and cultural influence, stereotypes, motivation, decision making, group dynamics, aggression, close relationships, social and affective neuroscience, social psychophysiology, emotions, prosocial behavior, health-related behavior, and personality and individual differences. Proposals that develop new theories or methods for understanding social behavior are highly encouraged. Research samples should represent substantial ranges of ethnicities, socioeconomic backgrounds, cultures, and other dimensions of human populations. Proposals involving non-human animals are considered only if the research offers clear and direct contributions to understanding human social behavior. The program does not fund research that seeks to improve clinical practice as its primary outcome, nor does it consider proposals with disease-related goals, including work on the etiology, diagnosis or treatment of physical or mental disease, abnormality, or malfunction in human beings or animals. Due July 15, 2020. January 15 and July 15 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 1. NSF: Biological Anthropology The Biological Anthropology Program supports basic research in areas related to human evolution and contemporary human biological variation. Research areas supported by the program include, but are not limited to, human genetic variation, human and nonhuman primate ecology and adaptability, human osteology and bone biology, human and nonhuman primate paleontology, functional anatomy, and primate socioecology. Grants supported in these areas are united by an underlying evolutionary framework, and often by a consideration of adaptation as a central theoretical theme. Proposals may also have a biocultural or bioarchaeological orientation. The program frequently serves as a bridge within NSF between the social and behavioral sciences and the natural and physical sciences, and proposals commonly are jointly reviewed and funded with other programs. Due July 20, 2020. January 20 and July 20 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 7. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: